Glial GLRX3 Enzyme Drives Chronic Oxaliplatin-Induced Pain in Aged Models

Chronic neuropathic pain remains a debilitating complication of modern oncology, affecting nearly half of all patients undergoing cancer treatment [1]. While advancements in chemotherapy have extended life expectancy, the resulting toxicities often lead to significant functional impairment and a diminished quality of life [2]. Older patients are particularly vulnerable to these effects, frequently experiencing more persistent and refractory symptoms following exposure to platinum-based agents [3]. Current management strategies are often limited by insufficient efficacy or intolerable side effects, highlighting a critical need for treatments that address the underlying mechanisms of nerve sensitization [4]. Recent investigations into the neurovascular unit and glial-neuronal interactions have begun to clarify how age-related physiological changes predispose certain individuals to chronic pain states [5]. A new study now offers fresh insights into the specific molecular pathways that sustain this age-biased neuropathy.